Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

详细信息    查看全文

• 作者：Nicholas T. Funderburg^a ; ^{nicholas.funderburg@osumc.edu} ; Grace A. McComsey^b ; ^c ; Manjusha Kulkarni^a ; Tammy Bannerman^a ; Jessica Mantini^a ; Bernadette Thornton^a ; Hui C. Liu^d ; Yafeng Zhang^d ; Qinghua Song^d ; Liang Fang^d ; Jason Dinoso^d ; Andrew Cheng^d ; Scott McCallister^d ; Marshall W. Fordyce^d ; Moupali Das^d
• 关键词：Inflammation ; Immune activation ; Biomarkers ; Tenofovir alafenamide
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：13
• 期：Complete
• 页码：321-327
• 全文大小：722 K
• 卷排序：13

文摘

Persons infected with HIV continue have residual immune activation and inflammation despite virologic suppression. Several markers of immune activation and inflammation are associated with mortality and cardiovascular disease (CVD). Decline in these markers is equivalent with tenofovir alafenamide and tenofovir disoproxil fumarate.Biomarkers of immune activation and inflammation are associated with non AIDS–associated comorbidities and all-cause mortality. TDF decreased inflammatory markers associated with cardiovascular risk in treatment-naïve individuals. Studies have demonstrated that TAF is as efficacious at virologic suppression as TDF, and safer regarding renal and bone toxicity, but treatment differences in decline of immune activation and inflammation have not been explored. Results of our study suggest that TAF is equivalent to TDF in reducing markers of immune activation and inflammation associated with all-cause mortality, while providing an improved renal and bone safety profile compared with TDF.